Collaborative and Licensing Agreements - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	$ 27,299	$ 19,683	$ 142,969	$ 121,096
Deferred revenue	35,200	13,000	35,200	13,000
Research collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	100	6,300	2,100	79,700
Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded			5,000	14,000
Royalties
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	27,200	13,400	135,900	27,400
Alexion Pharmaceuticals, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	7,300	5,800	20,200	16,400
Astellas
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded			5,000
Genentech
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded				2,500
Janssen
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	100	6,300	2,100	37,000
MorphoSys
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	2,100	1,300	5,600	16,400
Novartis
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded				41,100
Vir
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recorded	$ 17,800	$ 6,300	$ 110,100	$ 7,700